BioCryst Pharmaceuticals traded at $8.56 this Wednesday March 4th, decreasing $0.13 or 1.50 percent since the previous trading session. Looking back, over the last four weeks, BioCryst Pharmaceuticals lost 37.18 percent. Over the last 12 months, its price rose by 6.34 percent. Looking ahead, we forecast BioCryst Pharmaceuticals to be priced at 8.48 by the end of this quarter and at 7.73 in one year, according to Trading Economics global macro models projections and analysts expectations.
BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.